Allele-specific PCR for determination of IL28B genotype

Journal of Clinical Microbiology

Volumn 50, Issue 12, 2012, Pages 4144-4146

  Cook, Linda ^a   Diem, Kurt ^a   Kim, Woo ^a   Scott, John D ^a   Jerome, Keith R ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSINE; DNA; INTERLEUKIN 28B; THYMINE;

ALLELE; ARTICLE; CONTROLLED STUDY; DNA DETERMINATION; GENOTYPE; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; MATERIALS HANDLING; MEDICAL DECISION MAKING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUALITY CONTROL; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; STORAGE TEMPERATURE; WILD TYPE;

ALLELES; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERLEUKINS; POLYMERASE CHAIN REACTION;

HEPATITIS C VIRUS GENOTYPE 1;

EID: 84869233860     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02084-12     Document Type: Article

References (20)

1. Cariani E, et al. 2011. Interleukin 28B genotype determination using DNA from different sources: a simple and reliable tool for the epidemiological and clinical characterization of hepatitis C. J. Virol. Methods 178:235-238.
2. Doehring A, et al. 2010. Screening for IL28B gene variants identifies predictors of hepatitis C therapy success. Antiviral Ther. 15:1099-1106.
3. Fonseca-Coronado S, et al. 2011. Interleukin-28B genotyping by melt-mismatch amplification mutation assay PCR analysis using single nucleotide polymorphisms rs12979860 and rs8099917, a useful tool for prediction of therapy response in hepatitis C patients. J. Clin. Microbiol. 49:2706-2710.
4. Galmozzi E, et al. 2011. A tetra-primer amplification refractory mutation system polymerase chain reaction for the evaluation of rs12979860 IL28B genotype. J. Viral Hepat. 18:628-630.
5. Ge D, et al. 2009. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461:399-401.
6. Hoffman NG, Cook L, Atienza EE, Limaye AP, Jerome KR. 2008. Marked variability of BK virus load measurement using quantitative real-time PCR among commonly used assays. J. Clin. Microbiol. 46:2671-2680.
7. Ito K, et al. 2011. The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to pegylated alpha interferon/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with interleukin-28B. J. Clin. Microbiol. 49:1853-1860.
8. Kawaoka T, et al. 2011. Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b. J. Hepatol. 54:408-414.
9. Kovanda A, Poljak M. 2011. Real-time polymerase chain reaction assay based on high-resolution melting analysis for the determination of the rs12979860 polymorphism involved in hepatitis C treatment response. J. Virol. Methods 175:125-128.
10. Lange CM, Zeuzem S. 2011. IL28B single nucleotide polymorphisms in the treatment of hepatitis C. J. Hepatol. 55:692-701.
11. Nakamoto S, et al. 2011. Simple assay based on restriction fragment length polymorphism associated with IL28B in chronic hepatitis C patients. Scand. J. Gastroenterol. 46:955-961.
12. Rauch A, et al. 2010. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 138:1338-1345.
13. Scott J, et al. 2011. IL28B genotype effects during early treatment with peginterferon and ribavirin in difficult-to-treat hepatitis C virus infection. J. Infect. Dis. 204:419-425.
14. Smith KR, et al. 2011. Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. Genome Med. 3:57. doi:10.1186/gm273.
15. Stattermayer AF, et al. 2011. Impact of IL28B genotype on the early and sustained virologic response in treatment-naive patients with chronic hepatitis C. Clin. Gastroenterol. Hepatol 9:344-350.
16. Suppiah V, et al. 2009. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat. Genet. 41:1100-1104.
17. Tanaka Y, et al. 2009. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 41:1105-1109.
18. Thomas DL, et al. 2009. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461:798-801.
19. Tillmann HL, et al. 2010. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 139:1586-1592.
20. Urban TJ, et al. 2010. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 52:1888-1896.